<DOC>
<DOCNO>
EP-0010941
</DOCNO>
<TEXT>
<DATE>
19800514
</DATE>
<IPC-CLASSIFICATIONS>
<main>C07D-239/54</main> C07D-239/00 C07D-409/12 C07D-403/12 C07D-403/00 C07D-317/00 C07D-333/00 A61K-31/505 C07D-239/553 C07D-333/38 C07D-409/00 C07D-405/12 C07D-239/54 C07D-317/70 C07D-401/12 
</IPC-CLASSIFICATIONS>
<TITLE>
5-fluorouracil derivatives, preparation thereof and their pharmaceutical compositions.
</TITLE>
<APPLICANT>
fujisawa pharmaceutical cojp<sep>fujisawa pharmaceutical co. ltd. <sep>fujisawa pharmaceutical co., ltd.3, doshomachi 4-chome higashi-kuosaka-shi osaka 541 jp  <sep>fujisawa pharmaceutical co. ltd.<sep>
</APPLICANT>
<INVENTOR>
takaya takao<sep>tozuka zenzaburo<sep>takaya, takao<sep>tozuka, zenzaburo<sep>takaya, takaono. 5-87, suimeidai 1-chomekawanishi-shi, hyogo 666-01jp<sep>tozuka, zenzaburono. 16-13-121, kamishinden 4-chometoyonaka-shi, osaka 565jp<sep>takaya, takao<sep>tozuka, zenzaburo<sep>takaya, takaono. 5-87, suimeidai 1-chomekawanishi-shi, hyogo 666-01jp<sep>tozuka, zenzaburono. 16-13-121, kamishinden 4-chometoyonaka-shi, osaka 565jp<sep>
</INVENTOR>
<ABSTRACT>
the present invention provides compounds of the  general formula:-    wherein r is an optionally substituted bridged alicyclic  radical or a substituted lower alkyl radical, the substituent  being an optionally substituted bridged alicyclic group,  an amino, protected amino, lower alkoxy, acyl, lower  alkylthio, cyano(lower)alkylthio, arylthio or optionally  substituted heterocyclic radical or a carboxy and esterified  carboxy group, with the proviso, that when the substituent  is a carboxy or esterified carboxy group then the lower  alkyl radical contains 3 to 6 carbon atoms; or an unsubstituted  or substituted lower alkenyl radical, the substitutent  being an optionally substituted bridged alicyclic  group, an optionally substituted aryl radical or an  optionally substituted heterocyclic radical; or a halophenyl  radical; or an optionally substituted heterocyclic  radical.  the present invention also provides processes for  the preparation of these compounds and pharmaceutical  composition containing them.  furthermore, the present  invention is concerned with a method of treating cancer  which comprises administering these compounds to  mammals suffering from cancer.  
</ABSTRACT>
</TEXT>
</DOC>
